References
- Service FJ, Mc Mahon MM, O’Brien PC, et al. Functioning insulinoma – incidence, recurrence and long-term survival of patients: a 60-year study. Mayo Clin Proc. 1991;66(7):711–719.
- Iglesias P, Díez JJ. Management of endocrine disease: a clinical update on tumor-induced hypoglycemia. Eur J Endocrinol. 2014;170(4):R147–R157.
- Goode PN, Farndon JR, Anderson J, et al. Diazoxide in the management of patients with insulinoma. World J Surg. 1986;10(4):586–592.
- Maggio I, Mollica V, Brighi N, et al. The functioning side of the pancreas: a review on insulinomas. J Endocrinol Invest. 2020;43(2):139–148.
- Gill GV, Rauf O, MacFarlane IA. Diazoxide treatment for insulinoma: a national UK survey. Postgrad Med J. 1997; 73(864):640–641.
- Komatsu Y, Nakamura A, Takihata M, et al. Safety and tolerability of diazoxide in Japanese patients with hyperinsulinemic hypoglycemia. Endocr J. 2016; 63(3):311–314.
- Niitsu Y, Minami I, Izumiyama H, et al. Clinical outcomes of 20 Japanese patients with insulinoma treated with diazoxide. Endocr J. 2019; 66(2):149–155.
- Ito T, Igarashi H, Jensen RT. Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances. Best Pract Res Clin Gastroenterol. 2012;26(6):737–753.
- Vezzosi D, Bennet A, Courbon F, et al. Short- and long-term somatostatin analogue treatment in patients with hypoglycaemia related to endogenous hyperinsulinism. Clin Endocrinol (Oxf)). 2008;68(6):904–911.
- Matej A, Bujwid H, Wroński J. Glycemic control in patients with insulinoma. Hormones (Athens)). 2016;15(4):489–499.
- Gama R, Marks V, Wright J, et al. Octreotide exacerbated fasting hypoglycaemia in a patient with a proinsulinoma; the glucostatic importance of pancreatic glucagon. Clin Endocrinol (Oxf)). 1995; 43(1):117–120. discussion 120–2.
- Dimitriadis GK, Weickert MO, Randeva HS, et al. Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours. Endocr Rel Cancer. 2016;23(9):R423–R436.
- Brown E, Watkin D, Evans J, et al. Multidisciplinary management of refractory insulinomas. Clin Endocrinol. 2018;88(5):615–624.
- Tirosh A, Stemmer SM, Solomonov E, et al. Pasireotide for malignant insulinoma. Hormones (Athens)). 2016;15(2):271–276.